These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12548142)

  • 1. A Bayesian method based on clotting factor activity for the prediction of maintenance warfarin dosage regimens.
    Pitsiu M; Parker EM; Aarons L; Rowland M
    Ther Drug Monit; 2003 Feb; 25(1):36-40. PubMed ID: 12548142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting.
    Sasaki T; Tabuchi H; Higuchi S; Ieiri I
    Pharmacogenomics; 2009 Aug; 10(8):1257-66. PubMed ID: 19663670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of using warfarin plasma concentrations in Bayesian forecasting of prothrombin-time response.
    Lee C; Coleman RW; Mungall DR
    Clin Pharm; 1987 May; 6(5):406-12. PubMed ID: 3665392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methods for Predicting Warfarin Dose Requirements.
    Saffian SM; Wright DF; Roberts RL; Duffull SB
    Ther Drug Monit; 2015 Aug; 37(4):531-8. PubMed ID: 25549208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nomogram for dosing warfarin at steady state.
    Fredriks DA; Coleman RW
    Clin Pharm; 1991 Dec; 10(12):923-7. PubMed ID: 1773579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new regimen for starting warfarin therapy in out-patients.
    Oates A; Jackson PR; Austin CA; Channer KS
    Br J Clin Pharmacol; 1998 Aug; 46(2):157-61. PubMed ID: 9723825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of warfarin on the kinetics of the vitamin K-dependent clotting factors in rats.
    Vainieri H; Wingard LB
    J Pharmacol Exp Ther; 1977 May; 201(2):507-17. PubMed ID: 870684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of tecarfarin, a novel vitamin K antagonist oral anticoagulant.
    Albrecht D; Ellis D; Canafax DM; Combs D; Druzgala P; Milner PG; Midei MG
    Thromb Haemost; 2017 Apr; 117(4):706-717. PubMed ID: 28180234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
    Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
    Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steady-state clearance rates of warfarin and its enantiomers in therapeutically dosed patients.
    McAleer SD; Foondun AS; Feely M; Chrystyn H
    Chirality; 1997; 9(1):13-6. PubMed ID: 9094197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of Genotype on Warfarin Maintenance Dose Predictions Produced Using a Bayesian Dose Individualization Tool.
    Saffian SM; Duffull SB; Roberts RL; Tait RC; Black L; Lund KA; Thomson AH; Wright DF
    Ther Drug Monit; 2016 Dec; 38(6):677-683. PubMed ID: 27855133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualised medicine: why we need Bayesian dosing.
    Donagher J; Martin JH; Barras MA
    Intern Med J; 2017 May; 47(5):593-600. PubMed ID: 28503880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of warfarin at beginning doses on patients with valve replacement.
    Kudo T; Hashimoto M; Uchino T; Osada T; Furukawa K
    Artery; 1992; 19(6):344-52. PubMed ID: 1471923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of warfarin enantiomers: a search for intrasubject correlations.
    Wingard LB; O'Reilly RA; Levy G
    Clin Pharmacol Ther; 1978 Feb; 23(2):212-7. PubMed ID: 620483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Warfarin dosage requirements: prospective clinical trial of a method for prediction from the response to a single dose.
    Jupe DM; Peterson GM; Coleman RL; McLean S
    Br J Clin Pharmacol; 1988 May; 25(5):607-10. PubMed ID: 3044427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Joint Model for Vitamin K-Dependent Clotting Factors and Anticoagulation Proteins.
    Ooi QX; Wright DFB; Tait RC; Isbister GK; Duffull SB
    Clin Pharmacokinet; 2017 Dec; 56(12):1555-1566. PubMed ID: 28409488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian pharmacokinetic/pharmacodynamic forecasting of prothrombin response to warfarin therapy: preliminary evaluation.
    Svec JM; Coleman RW; Mungall DR; Ludden TM
    Ther Drug Monit; 1985; 7(2):174-80. PubMed ID: 4024210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations.
    Palareti G; Legnani C
    Clin Pharmacokinet; 1996 Apr; 30(4):300-13. PubMed ID: 8983860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective study of an aggressive warfarin dosing algorithm to reach and maintain INR 2 to 3 after heart valve surgery.
    Meijer K; Kim YK; Carter D; Schulman S
    Thromb Haemost; 2011 Feb; 105(2):232-8. PubMed ID: 21173999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Warfarin maintenance dose adjustment with indirect pharmacodynamic model in rats.
    Cao YG; Liu XQ; Chen YC; Hao K; Wang GJ
    Eur J Pharm Sci; 2007 Feb; 30(2):175-80. PubMed ID: 17169538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.